Aktieanalys

Scandinavian ChemoTech: TO3 outcome - Redeye

{newsItem.title}

Redeye Publicerad: 26 Apr 2023 14:19

Redeye comments on Scandinavian ChemoTech’s TO3 exercise, which generated SEK7.44m before issue-related costs. With a subscription rate of 65.14%, the exercise resulted in the addition of 1,553,264 new shares. In light of this news, we have updated our valuation accordingly.

Länk till analysen i sin helhet: https://www.redeye.se/research/897297/scandinavian-chemotech-to3-outcome?utm_source=finwire&utm_medium=RSS

Nyheter om ChemoTech

Läses av andra just nu

Om aktien ChemoTech

Senaste nytt